Pancreatic Cancer Research

ResearcherThomas Jefferson UniversityNo recent work listed

Hwyda A. Arafat

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3400-7705; OpenAlex author ID A5088939674. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
2
Collaborators
17
Papers, trials and grants by year

2011: 5 papers · 2012: none · 2013: 2 papers · 2014: 3 papers · 2015: none · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 13

  1. Angiotensin blockade therapy and survival in pancreatic cancer: a population study. Co-author DOI 10.1186/s12885-022-09200-4↗
  2. Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Ac… Last author DOI 10.1155/2016/1407840↗
  3. Hypothyroidism in Pancreatic Cancer: Role of Exogenous Thyroid Hormone in Tumor Invasion-Preliminary Observations. Last author DOI 10.1155/2016/2454989↗
  4. Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s11605-013-2326-y↗
  5. Overexpressing TNF-alpha in pancreatic ductal adenocarcinoma cells and fibroblasts modifies cell survival and reduces fatty acid synthesis via downregulation o… Last author DOI 10.1007/s11605-013-2370-7↗
  6. Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma. Last author DOI 10.1111/jgh.12561↗
  7. Circadian gene expression and clinicopathologic correlates in pancreatic cancer. Last author DOI 10.1007/s11605-012-2112-2↗
  8. Differential expression of cytochrome P450 omega-hydroxylase isoforms and their association with clinicopathological features in pancreatic ductal adenocarcino… Last author DOI 10.1245/s10434-013-3128-x↗
  9. Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer. Co-author DOI 10.1016/j.surg.2011.05.011↗
  10. Angiotensin II type 2 receptor blockade inhibits fatty acid synthase production through activation of AMP-activated protein kinase in pancreatic cancer cells. Last author DOI 10.1016/j.surg.2011.06.002↗
  11. Serum monocyte chemoattractant protein-1 in pancreatic cancer. Last author DOI 10.1155/2011/518394↗
  12. Expression and regulation of nicotine receptor and osteopontin isoforms in human pancreatic ductal adenocarcinoma. Last author DOI 10.14670/hh-26.893↗
  13. Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition. Co-author DOI 10.4161/cc.10.21.17895↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Charles J. Yeo · 10 shared papers, 2011–2016 · strength 0.41
  2. Daniel M. Relles · 4 shared papers, 2013–2016 · strength 0.20
  3. Harish Lavu · 2 shared papers, 2011–2022 · strength 0.19
  4. Konrad Sarosiek · 4 shared papers, 2013–2016 · strength 0.18
  5. Christopher Y. Kang · 4 shared papers, 2013–2016 · strength 0.18
  6. Daniel Z. Louis · 1 shared paper, 2022 · strength 0.16
  7. Scott W. Keith · 1 shared paper, 2022 · strength 0.16
  8. Shivam Saxena · 3 shared papers, 2013–2016 · strength 0.14
  9. Ankit V. Gandhi · 3 shared papers, 2013–2016 · strength 0.14
  10. Mazhar Salim Al Zoubi · 2 shared papers, 2014 · strength 0.08
  11. Mon‐Li Chu · 2 shared papers, 2011–2014 · strength 0.06
  12. Jennifer Sullivan · 2 shared papers, 2011 · strength 0.06
  13. Thomas E. Kowalski · 1 shared paper, 2014 · strength 0.04
  14. Ali A. Siddiqui · 1 shared paper, 2014 · strength 0.04
  15. Amy McGhee · 1 shared paper, 2011 · strength 0.03
  16. Michael P. Lisanti · 1 shared paper, 2011 · strength 0.03
  17. Ahmed F. Salem · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.